Jennifer A Whitaker1, Sameer A Parikh2, Tait D Shanafelt3, Neil E Kay2, Richard B Kennedy4, Diane E Grill5, Krista M Goergen5, Timothy G Call2, Saad S Kendarian2, Wei Ding2, Gregory A Poland4. 1. Molecular Virology and Microbiology and Medicine, Infectious Diseases, Baylor College of Medicine One Baylor Plaza, MS-280, Houston, TX 77030, USA; Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: jennifer.whitaker@bcm.edu. 2. Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. 3. Division of Hematology, Stanford University School of Medicine, 500 Pasteur Drive, Stanford, CA 94305, USA. 4. Division of General Internal Medicine and Vaccine Research Group, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. 5. Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Abstract
BACKGROUND: Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL). METHODS: A prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays. RESULTS: Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL. CONCLUSIONS: Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL.
BACKGROUND: Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL). METHODS: A prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays. RESULTS: Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL. CONCLUSIONS: Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL.
Authors: Anna S Dean; Cameron R M Moffatt; Alexander Rosewell; Dominic E Dwyer; Richard I Lindley; Robert Booy; C Raina MacIntyre Journal: Vaccine Date: 2009-04-02 Impact factor: 3.641
Authors: Alexander W Hauswirth; Julia Almeida; Wendy G Nieto; Cristina Teodosio; Arancha Rodriguez-Caballero; Alfonso Romero; Antonio López; Paulino Fernandez-Navarro; Tomas Vega; Martin Perez-Andres; Peter Valent; Ulrich Jäger; Alberto Orfao Journal: Am J Hematol Date: 2012-06-08 Impact factor: 10.047
Authors: Andy C Rawstron; Tait Shanafelt; Mark C Lanasa; Ola Landgren; Curtis Hanson; Alberto Orfao; Peter Hillmen; Paolo Ghia Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Clare Sun; Jin Gao; Laura Couzens; Xin Tian; Mohammed Z Farooqui; Maryna C Eichelberger; Adrian Wiestner Journal: JAMA Oncol Date: 2016-12-01 Impact factor: 31.777
Authors: Sebastian Francis; Mamatha Karanth; Guy Pratt; Jane Starczynski; Laura Hooper; Chris Fegan; Chris Pepper; David Valcarcel; Donald W Milligan; Julio Delgado Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: J Jurlander; P de Nully Brown; P S Skov; J Henrichsen; I Heron; N Obel; B T Mortensen; M M Hansen; C H Geisler; H J Nielsen Journal: Leukemia Date: 1995-11 Impact factor: 11.528
Authors: Zoe L Lyski; Sunny Kim; David Xthona Lee; David Sampson; Hans P Raué; Vikram Raghunathan; Debbie Ryan; Amanda E Brunton; Mark K Slifka; William B Messer; Stephen E Spurgeon Journal: medRxiv Date: 2021-09-07
Authors: Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao Journal: Leukemia Date: 2022-06-22 Impact factor: 12.883
Authors: Vanessa Piechotta; Sibylle C Mellinghoff; Caroline Hirsch; Alice Brinkmann; Claire Iannizzi; Nina Kreuzberger; Anne Adams; Ina Monsef; Jannik Stemler; Oliver A Cornely; Paul J Bröckelmann; Nicole Skoetz Journal: Blood Cancer J Date: 2022-05-31 Impact factor: 9.812
Authors: Eli Muchtar; Amber B Koehler; Michael J Johnson; Kari G Rabe; Wei Ding; Timothy G Call; Jose F Leis; Saad S Kenderian; Suzanne R Hayman; Yucai Wang; Paul J Hampel; Matthew A Holets; Heather C Darby; Susan L Slager; Neil E Kay; Congrong Miao; Jennifer Canniff; Jennifer A Whitaker; Myron J Levin; D Scott Schmid; Richard B Kennedy; Adriana Weinberg; Sameer A Parikh Journal: Am J Hematol Date: 2021-11-05 Impact factor: 13.265
Authors: Zoe L Lyski; Myung Sun Kim; David Xthona Lee; David Sampson; Hans-Peter Raué; Vikram Raghunathan; Debbie Ryan; Amanda E Brunton; Mark K Slifka; William B Messer; Stephen E Spurgeon Journal: Case Rep Hematol Date: 2022-02-04